 Benjamin Frank
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 16 | 2024 | 1747 | 3.370 |
Why?
| | Heart Defects, Congenital | 13 | 2024 | 747 | 1.910 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2022 | 383 | 1.720 |
Why?
| | Hernias, Diaphragmatic, Congenital | 2 | 2023 | 203 | 1.350 |
Why?
| | Fontan Procedure | 5 | 2024 | 172 | 1.270 |
Why?
| | Endothelin-1 | 2 | 2022 | 175 | 1.240 |
Why?
| | Ventricular Dysfunction, Right | 4 | 2023 | 228 | 1.100 |
Why?
| | Kynurenine | 3 | 2024 | 105 | 1.080 |
Why?
| | Pulmonary Artery | 8 | 2025 | 1030 | 1.060 |
Why?
| | Tryptophan | 3 | 2024 | 171 | 1.040 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 516 | 1.020 |
Why?
| | Cardiac Surgical Procedures | 6 | 2024 | 493 | 0.970 |
Why?
| | Infant | 22 | 2025 | 8912 | 0.940 |
Why?
| | Echocardiography | 6 | 2024 | 623 | 0.920 |
Why?
| | Acetamides | 1 | 2024 | 36 | 0.890 |
Why?
| | Cardiopulmonary Bypass | 7 | 2025 | 192 | 0.870 |
Why?
| | Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.870 |
Why?
| | Citrulline | 1 | 2024 | 43 | 0.860 |
Why?
| | Pyrazines | 1 | 2024 | 86 | 0.860 |
Why?
| | Nitric Oxide | 3 | 2024 | 881 | 0.840 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2024 | 281 | 0.840 |
Why?
| | Heart Ventricles | 9 | 2024 | 765 | 0.830 |
Why?
| | Blood Proteins | 2 | 2020 | 239 | 0.800 |
Why?
| | Arginine | 1 | 2024 | 259 | 0.790 |
Why?
| | Aortic Coarctation | 2 | 2023 | 82 | 0.780 |
Why?
| | Heart Bypass, Right | 1 | 2022 | 17 | 0.770 |
Why?
| | Hemodynamics | 10 | 2025 | 1077 | 0.770 |
Why?
| | Infant, Premature, Diseases | 2 | 2023 | 93 | 0.770 |
Why?
| | Ventricular Function, Left | 4 | 2023 | 524 | 0.690 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2020 | 66 | 0.690 |
Why?
| | Child | 27 | 2024 | 20636 | 0.680 |
Why?
| | Heart Diseases | 1 | 2023 | 345 | 0.670 |
Why?
| | Heart Function Tests | 1 | 2019 | 59 | 0.660 |
Why?
| | Prospective Studies | 11 | 2024 | 7035 | 0.640 |
Why?
| | Infant, Newborn | 14 | 2025 | 5688 | 0.630 |
Why?
| | Scurvy | 1 | 2019 | 14 | 0.620 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 26 | 0.620 |
Why?
| | Biomarkers | 8 | 2024 | 3874 | 0.600 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2019 | 126 | 0.580 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2023 | 374 | 0.580 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 329 | 0.570 |
Why?
| | Humans | 55 | 2025 | 128019 | 0.560 |
Why?
| | Pediatrics | 2 | 2024 | 1044 | 0.550 |
Why?
| | Ventricular Remodeling | 1 | 2019 | 254 | 0.530 |
Why?
| | Treatment Outcome | 11 | 2025 | 10110 | 0.470 |
Why?
| | Retrospective Studies | 14 | 2025 | 14404 | 0.460 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2022 | 183 | 0.420 |
Why?
| | Computed Tomography Angiography | 2 | 2025 | 115 | 0.420 |
Why?
| | Pain | 1 | 2019 | 748 | 0.410 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.390 |
Why?
| | Adolescent | 14 | 2024 | 20158 | 0.380 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2025 | 117 | 0.380 |
Why?
| | Ventricular Function, Right | 3 | 2023 | 274 | 0.370 |
Why?
| | Male | 25 | 2025 | 62757 | 0.370 |
Why?
| | Hypoxia | 3 | 2024 | 1034 | 0.360 |
Why?
| | Pulmonary Veins | 2 | 2023 | 93 | 0.360 |
Why?
| | Atrial Function, Right | 2 | 2021 | 12 | 0.350 |
Why?
| | Heart Failure | 1 | 2024 | 2141 | 0.350 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 481 | 0.340 |
Why?
| | Myocardial Contraction | 3 | 2020 | 333 | 0.340 |
Why?
| | Female | 24 | 2025 | 68016 | 0.320 |
Why?
| | Microfilament Proteins | 4 | 2003 | 125 | 0.320 |
Why?
| | Pulmonary Valve | 1 | 2010 | 93 | 0.320 |
Why?
| | Postoperative Complications | 5 | 2021 | 2456 | 0.310 |
Why?
| | Case-Control Studies | 4 | 2024 | 3324 | 0.290 |
Why?
| | Palliative Care | 3 | 2025 | 714 | 0.290 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 2 | 2025 | 24 | 0.280 |
Why?
| | Predictive Value of Tests | 5 | 2025 | 1934 | 0.280 |
Why?
| | Length of Stay | 3 | 2024 | 1114 | 0.280 |
Why?
| | Tissue Engineering | 1 | 2010 | 394 | 0.260 |
Why?
| | Child, Preschool | 9 | 2024 | 10378 | 0.260 |
Why?
| | Morbidity | 2 | 2024 | 301 | 0.260 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2023 | 184 | 0.250 |
Why?
| | Carrier Proteins | 4 | 2003 | 730 | 0.250 |
Why?
| | Hemorrhage | 2 | 2021 | 643 | 0.250 |
Why?
| | Vascular Stiffness | 2 | 2021 | 463 | 0.250 |
Why?
| | Proteomics | 2 | 2023 | 1008 | 0.250 |
Why?
| | Magnetic Resonance Imaging | 7 | 2024 | 3371 | 0.240 |
Why?
| | Multidetector Computed Tomography | 1 | 2025 | 32 | 0.230 |
Why?
| | SOXF Transcription Factors | 1 | 2024 | 16 | 0.230 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.230 |
Why?
| | Norwood Procedures | 1 | 2025 | 29 | 0.230 |
Why?
| | Serotonin | 2 | 2024 | 317 | 0.230 |
Why?
| | Graft Occlusion, Vascular | 1 | 2025 | 39 | 0.230 |
Why?
| | Echocardiography, Doppler | 1 | 2025 | 108 | 0.220 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 777 | 0.220 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 25 | 0.220 |
Why?
| | Prognosis | 2 | 2023 | 3766 | 0.210 |
Why?
| | History, 21st Century | 1 | 2024 | 177 | 0.210 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 35 | 0.210 |
Why?
| | History, 20th Century | 1 | 2024 | 285 | 0.210 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2023 | 17 | 0.210 |
Why?
| | Models, Cardiovascular | 2 | 2024 | 190 | 0.210 |
Why?
| | Vascular Resistance | 1 | 2024 | 366 | 0.210 |
Why?
| | Stroke Volume | 2 | 2023 | 588 | 0.200 |
Why?
| | Infant, Extremely Premature | 1 | 2023 | 60 | 0.200 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 140 | 0.200 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2022 | 40 | 0.200 |
Why?
| | Atrioventricular Block | 1 | 2022 | 35 | 0.200 |
Why?
| | Fetal Diseases | 1 | 2023 | 156 | 0.190 |
Why?
| | Phenylpropionates | 1 | 2022 | 16 | 0.190 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 108 | 0.190 |
Why?
| | Pyridazines | 1 | 2022 | 50 | 0.190 |
Why?
| | Protein Conformation | 2 | 2003 | 853 | 0.190 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2003 | 510 | 0.190 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 17 | 0.190 |
Why?
| | Phosphoproteins | 1 | 2003 | 328 | 0.180 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 260 | 0.180 |
Why?
| | Ventricular Function | 1 | 2021 | 61 | 0.180 |
Why?
| | Postoperative Period | 1 | 2022 | 322 | 0.180 |
Why?
| | Administration, Inhalation | 2 | 2021 | 661 | 0.180 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 89 | 0.170 |
Why?
| | Pulmonary Atresia | 1 | 2020 | 19 | 0.170 |
Why?
| | Metabolomics | 3 | 2021 | 599 | 0.170 |
Why?
| | Preoperative Period | 1 | 2020 | 113 | 0.170 |
Why?
| | Proteome | 1 | 2024 | 430 | 0.170 |
Why?
| | Societies, Medical | 1 | 2024 | 741 | 0.170 |
Why?
| | Heart Atria | 1 | 2021 | 127 | 0.170 |
Why?
| | Risk Factors | 4 | 2023 | 9696 | 0.170 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 215 | 0.170 |
Why?
| | Electrophysiological Phenomena | 1 | 2019 | 51 | 0.160 |
Why?
| | Lung | 3 | 2023 | 3745 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2023 | 495 | 0.160 |
Why?
| | Gingiva | 1 | 2019 | 25 | 0.160 |
Why?
| | Mechanical Phenomena | 1 | 2019 | 83 | 0.160 |
Why?
| | Regional Blood Flow | 1 | 2021 | 457 | 0.160 |
Why?
| | Coronary Care Units | 1 | 2018 | 16 | 0.160 |
Why?
| | Infant, Premature | 2 | 2023 | 536 | 0.150 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 222 | 0.150 |
Why?
| | Transcriptome | 1 | 2025 | 879 | 0.150 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 365 | 0.150 |
Why?
| | Cholecalciferol | 1 | 2019 | 56 | 0.150 |
Why?
| | Chest Pain | 1 | 2019 | 89 | 0.150 |
Why?
| | Alkaline Phosphatase | 1 | 2019 | 142 | 0.150 |
Why?
| | Ascorbic Acid | 1 | 2019 | 119 | 0.150 |
Why?
| | Endotoxemia | 1 | 2019 | 82 | 0.150 |
Why?
| | Endotoxins | 1 | 2019 | 215 | 0.150 |
Why?
| | Biomedical Research | 1 | 2024 | 632 | 0.150 |
Why?
| | Cohort Studies | 2 | 2024 | 5378 | 0.140 |
Why?
| | Vasodilator Agents | 1 | 2019 | 323 | 0.140 |
Why?
| | Heart Transplantation | 1 | 2023 | 711 | 0.140 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 488 | 0.140 |
Why?
| | Leg | 1 | 2019 | 236 | 0.140 |
Why?
| | Iron | 1 | 2019 | 282 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 734 | 0.130 |
Why?
| | Risk | 1 | 2019 | 850 | 0.130 |
Why?
| | Swine | 3 | 2025 | 742 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 452 | 0.130 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 1997 | 101 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1194 | 0.120 |
Why?
| | Actins | 3 | 2003 | 401 | 0.120 |
Why?
| | Intubation, Intratracheal | 1 | 1997 | 238 | 0.120 |
Why?
| | Down Syndrome | 1 | 2021 | 469 | 0.120 |
Why?
| | Lung Diseases | 1 | 2021 | 713 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2019 | 531 | 0.120 |
Why?
| | Time Factors | 3 | 2021 | 6479 | 0.110 |
Why?
| | Stents | 2 | 2025 | 504 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 944 | 0.110 |
Why?
| | Blood Pressure | 1 | 2019 | 1711 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2019 | 705 | 0.100 |
Why?
| | Amino Acid Sequence | 4 | 2003 | 2042 | 0.090 |
Why?
| | Molecular Sequence Data | 4 | 2003 | 2820 | 0.090 |
Why?
| | Diastole | 2 | 2022 | 148 | 0.090 |
Why?
| | Purines | 2 | 2022 | 168 | 0.090 |
Why?
| | Drainage | 1 | 2011 | 165 | 0.090 |
Why?
| | Bile Duct Neoplasms | 1 | 2011 | 99 | 0.090 |
Why?
| | Adult | 3 | 2023 | 35176 | 0.090 |
Why?
| | Cell Count | 1 | 2010 | 310 | 0.080 |
Why?
| | Anastomosis, Surgical | 2 | 2021 | 149 | 0.080 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2002 | 251 | 0.080 |
Why?
| | Cholestasis | 1 | 2011 | 228 | 0.080 |
Why?
| | Metabolome | 2 | 2021 | 319 | 0.070 |
Why?
| | Peptide Fragments | 2 | 2003 | 688 | 0.070 |
Why?
| | Keratan Sulfate | 1 | 2006 | 1 | 0.070 |
Why?
| | Histidine | 2 | 2003 | 58 | 0.060 |
Why?
| | Synovial Fluid | 1 | 2006 | 66 | 0.060 |
Why?
| | Protein Folding | 3 | 2002 | 266 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 129 | 0.060 |
Why?
| | Circular Dichroism | 2 | 2002 | 148 | 0.060 |
Why?
| | Organ Specificity | 1 | 2025 | 290 | 0.060 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 211 | 0.060 |
Why?
| | Osteoarthritis | 1 | 2006 | 166 | 0.060 |
Why?
| | Language Development | 1 | 2024 | 64 | 0.050 |
Why?
| | Vena Cava, Inferior | 1 | 2024 | 67 | 0.050 |
Why?
| | Syndrome | 1 | 2024 | 332 | 0.050 |
Why?
| | Erythrocyte Membrane | 1 | 2003 | 49 | 0.050 |
Why?
| | Models, Molecular | 3 | 2003 | 1482 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3625 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2337 | 0.050 |
Why?
| | Serine | 1 | 2003 | 135 | 0.050 |
Why?
| | Binding Sites | 2 | 2003 | 1241 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2002 | 835 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 465 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2024 | 417 | 0.050 |
Why?
| | Tadalafil | 1 | 2022 | 7 | 0.050 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 82 | 0.050 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2022 | 36 | 0.050 |
Why?
| | Phenylalanine | 1 | 2002 | 65 | 0.050 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2021 | 16 | 0.050 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 186 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 358 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2002 | 280 | 0.040 |
Why?
| | Niacinamide | 1 | 2021 | 73 | 0.040 |
Why?
| | Arterial Pressure | 1 | 2021 | 116 | 0.040 |
Why?
| | Methionine | 1 | 2021 | 157 | 0.040 |
Why?
| | Gestational Age | 1 | 2023 | 868 | 0.040 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2020 | 34 | 0.040 |
Why?
| | Survival Rate | 2 | 2011 | 1870 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 39 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 936 | 0.040 |
Why?
| | Systole | 1 | 2020 | 190 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2020 | 137 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 182 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 346 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1681 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 634 | 0.040 |
Why?
| | Time | 1 | 2019 | 75 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1012 | 0.040 |
Why?
| | Animals | 5 | 2025 | 34487 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 377 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 607 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1559 | 0.040 |
Why?
| | Myocardium | 1 | 2023 | 967 | 0.040 |
Why?
| | Escherichia coli | 1 | 2002 | 766 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1681 | 0.040 |
Why?
| | Aorta | 1 | 2020 | 408 | 0.040 |
Why?
| | Electrophysiologic Techniques, Cardiac | 1 | 2018 | 78 | 0.040 |
Why?
| | Nevada | 1 | 1997 | 9 | 0.040 |
Why?
| | Poisson Distribution | 1 | 1997 | 73 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1088 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 662 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2018 | 404 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1997 | 316 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1826 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1482 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1997 | 201 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2018 | 529 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1306 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 844 | 0.030 |
Why?
| | Oxygen | 1 | 2018 | 899 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2509 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4853 | 0.020 |
Why?
| | Retreatment | 1 | 2011 | 69 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3100 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2011 | 104 | 0.020 |
Why?
| | Catheterization | 1 | 2011 | 171 | 0.020 |
Why?
| | Chickens | 2 | 2002 | 187 | 0.020 |
Why?
| | Incidence | 1 | 1997 | 2614 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3223 | 0.020 |
Why?
| | United States | 1 | 2024 | 13785 | 0.020 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2006 | 9 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 2105 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 776 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 12281 | 0.010 |
Why?
| | Autoantigens | 1 | 2006 | 416 | 0.010 |
Why?
| | Knee Joint | 1 | 2006 | 366 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 2002 | 127 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 328 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 367 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 354 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2002 | 180 | 0.010 |
Why?
| | Titrimetry | 1 | 1999 | 10 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1999 | 72 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7029 | 0.010 |
Why?
| | Static Electricity | 1 | 1999 | 115 | 0.010 |
Why?
| | Solvents | 1 | 1999 | 107 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2002 | 378 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 1999 | 210 | 0.010 |
Why?
| | Temperature | 1 | 2002 | 628 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1286 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 340 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1617 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1999 | 541 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 1943 | 0.010 |
Why?
| | Thermodynamics | 1 | 1999 | 407 | 0.010 |
Why?
| | Software | 1 | 2002 | 606 | 0.010 |
Why?
| | Aged | 1 | 2011 | 21892 | 0.010 |
Why?
| | Middle Aged | 1 | 2011 | 30812 | 0.010 |
Why?
|
|
Frank's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|